Literature DB >> 25217476

Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis.

Daryle J DePianto1, Sanjay Chandriani2, Alexander R Abbas1, Guiquan Jia1, Elsa N N'Diaye1, Patrick Caplazi1, Steven E Kauder1, Sabyasachi Biswas1, Satyajit K Karnik3, Connie Ha1, Zora Modrusan1, Michael A Matthay4, Jasleen Kukreja5, Harold R Collard4, Jackson G Egen1, Paul J Wolters4, Joseph R Arron1.   

Abstract

BACKGROUND: There is microscopic spatial and temporal heterogeneity of pathological changes in idiopathic pulmonary fibrosis (IPF) lung tissue, which may relate to heterogeneity in pathophysiological mediators of disease and clinical progression. We assessed relationships between gene expression patterns, pathological features, and systemic biomarkers to identify biomarkers that reflect the aggregate disease burden in patients with IPF.
METHODS: Gene expression microarrays (N=40 IPF; 8 controls) and immunohistochemical analyses (N=22 IPF; 8 controls) of lung biopsies. Clinical characterisation and blood biomarker levels of MMP3 and CXCL13 in a separate cohort of patients with IPF (N=80).
RESULTS: 2940 genes were significantly differentially expressed between IPF and control samples (|fold change| >1.5, p<0.05). Two clusters of co-regulated genes related to bronchiolar epithelium or lymphoid aggregates exhibited substantial heterogeneity within the IPF population. Gene expression in bronchiolar and lymphoid clusters corresponded to the extent of bronchiolisation and lymphoid aggregates determined by immunohistochemistry in adjacent tissue sections. Elevated serum levels of MMP3, encoded in the bronchiolar cluster, and CXCL13, encoded in the lymphoid cluster, corresponded to disease severity and shortened survival time (p<10(-7) for MMP3 and p<10(-5) for CXCL13; Cox proportional hazards model).
CONCLUSIONS: Microscopic pathological heterogeneity in IPF lung tissue corresponds to specific gene expression patterns related to bronchiolisation and lymphoid aggregates. MMP3 and CXCL13 are systemic biomarkers that reflect the aggregate burden of these pathological features across total lung tissue. These biomarkers may have clinical utility as prognostic and/or surrogate biomarkers of disease activity in interventional studies in IPF. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis

Mesh:

Substances:

Year:  2014        PMID: 25217476      PMCID: PMC4472447          DOI: 10.1136/thoraxjnl-2013-204596

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  38 in total

1.  Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis.

Authors:  Christopher J Lettieri; Steven D Nathan; Scott D Barnett; Shahzad Ahmad; Andrew F Shorr
Journal:  Chest       Date:  2006-03       Impact factor: 9.410

2.  A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis.

Authors:  L C Watters; T E King; M I Schwarz; J A Waldron; R E Stanford; R M Cherniack
Journal:  Am Rev Respir Dis       Date:  1986-01

3.  The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis.

Authors:  M D Sternlicht; A Lochter; C J Sympson; B Huey; J P Rougier; J W Gray; D Pinkel; M J Bissell; Z Werb
Journal:  Cell       Date:  1999-07-23       Impact factor: 41.582

4.  Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis.

Authors:  Camille Taillé; Sabine Grootenboer-Mignot; Céline Boursier; Laurence Michel; Marie-Pierre Debray; Jérôme Fagart; Lorena Barrientos; Arnaud Mailleux; Natacha Cigna; Florence Tubach; Joëlle Marchal-Sommé; Paul Soler; Sylvie Chollet-Martin; Bruno Crestani
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

5.  Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis.

Authors:  Motohiro Kimura; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Osamu Nishiyama; Hiromichi Aso; Koji Sakamoto; Yoshinori Hasegawa
Journal:  Respiration       Date:  2012-12-19       Impact factor: 3.580

6.  Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients.

Authors:  Jianmin Xue; Daniel J Kass; Jessica Bon; Louis Vuga; Jiangning Tan; Eva Csizmadia; Leo Otterbein; Makoto Soejima; Marc C Levesque; Kevin F Gibson; Naftali Kaminski; Joseph M Pilewski; Michael Donahoe; Frank C Sciurba; Steven R Duncan
Journal:  J Immunol       Date:  2013-07-19       Impact factor: 5.422

7.  A multidimensional index and staging system for idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard
Journal:  Ann Intern Med       Date:  2012-05-15       Impact factor: 25.391

8.  Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.

Authors:  Joyce S Lee; Eunice J Kim; Kara L Lynch; Brett Elicker; Christopher J Ryerson; Tamiko R Katsumoto; Anthony K Shum; Paul J Wolters; Stefania Cerri; Luca Richeldi; Kirk D Jones; Talmadge E King; Harold R Collard
Journal:  Respir Med       Date:  2012-11-24       Impact factor: 3.415

9.  Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis.

Authors:  Ivana V Yang; Christopher D Coldren; Sonia M Leach; Max A Seibold; Elissa Murphy; Jia Lin; Rachel Rosen; Amanda J Neidermyer; David F McKean; Steve D Groshong; Carlyne Cool; Gregory P Cosgrove; David A Lynch; Kevin K Brown; Marvin I Schwarz; Tasha E Fingerlin; David A Schwartz
Journal:  Thorax       Date:  2013-06-19       Impact factor: 9.139

10.  The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium.

Authors:  Max A Seibold; Russell W Smith; Cydney Urbanek; Steve D Groshong; Gregory P Cosgrove; Kevin K Brown; Marvin I Schwarz; David A Schwartz; Susan D Reynolds
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

View more
  89 in total

1.  Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis.

Authors:  Brijendra Singh; Rajesh K Kasam; Vishwaraj Sontake; Thomas A Wynn; Satish K Madala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

2.  Fibrocytes Regulate Wilms Tumor 1-Positive Cell Accumulation in Severe Fibrotic Lung Disease.

Authors:  Vishwaraj Sontake; Shiva K Shanmukhappa; Betsy A DiPasquale; Geereddy B Reddy; Mario Medvedovic; William D Hardie; Eric S White; Satish K Madala
Journal:  J Immunol       Date:  2015-09-14       Impact factor: 5.422

3.  Reply: the bleomycin model: in pursuit of relevant biomakers.

Authors:  Yasmina Bauer; Oliver Nayler; Naftali Kaminski
Journal:  Am J Respir Cell Mol Biol       Date:  2015-11       Impact factor: 6.914

4.  Fibrosis, gene expression and orbital inflammatory disease.

Authors:  James T Rosenbaum; Dongseok Choi; David J Wilson; Hans E Grossniklaus; Christina A Harrington; Roger A Dailey; John D Ng; Eric A Steele; Craig N Czyz; Jill A Foster; David Tse; Chris Alabiad; Sander Dubovy; Prashant Parekh; Gerald J Harris; Michael Kazim; Payal Patel; Valerie White; Peter Dolman; Deepak P Edward; Hind Alkatan; Hailah Al Hussain; Dinesh Selva; Patrick Yeatts; Bobby Korn; Don Kikkawa; Patrick Stauffer; Stephen R Planck
Journal:  Br J Ophthalmol       Date:  2015-06-02       Impact factor: 4.638

5.  A new computational drug repurposing method using established disease-drug pair knowledge.

Authors:  Nafiseh Saberian; Azam Peyvandipour; Michele Donato; Sahar Ansari; Sorin Draghici
Journal:  Bioinformatics       Date:  2019-10-01       Impact factor: 6.937

6.  Hsp90 regulation of fibroblast activation in pulmonary fibrosis.

Authors:  Vishwaraj Sontake; Yunguan Wang; Rajesh K Kasam; Debora Sinner; Geereddy B Reddy; Anjaparavanda P Naren; Francis X McCormack; Eric S White; Anil G Jegga; Satish K Madala
Journal:  JCI Insight       Date:  2017-02-23

7.  Wilms' tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease.

Authors:  Vishwaraj Sontake; Rajesh K Kasam; Debora Sinner; Thomas R Korfhagen; Geereddy B Reddy; Eric S White; Anil G Jegga; Satish K Madala
Journal:  JCI Insight       Date:  2018-08-23

8.  Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s).

Authors:  Olga B Garbuzenko; Vera Ivanova; Vladislav Kholodovych; David C Reimer; Kenneth R Reuhl; Edvard Yurkow; Derek Adler; Tamara Minko
Journal:  Nanomedicine       Date:  2017-04-19       Impact factor: 5.307

9.  Epigenetic Regulation of Caveolin-1 Gene Expression in Lung Fibroblasts.

Authors:  Yan Y Sanders; Hui Liu; Anne M Scruggs; Steven R Duncan; Steven K Huang; Victor J Thannickal
Journal:  Am J Respir Cell Mol Biol       Date:  2017-01       Impact factor: 6.914

10.  Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice.

Authors:  David M Habiel; Milena S Espindola; Ana L Coelho; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2018-02-17       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.